Candida esophagitis as the cause of swallowing disturbances in an 85-year-old patient with myasthenia gravis.
Authors: Ebert S, Schweiger KP, Nau R An 85-year-old man with myasthenia gravis was successfully treated with methotrexate (10 mg/week), pyridostigmine and prednisolone (0-30 mg/day) for over 10 years. Then, he developed dysphagia and lost weight. Gastroscopy revealed Candida esophagitis. The patient received nystatin for 2 weeks. Methotrexate was stopped, and immunosuppressive therapy was continued with prednisolone alone. The patient has now remained in good condition for over 1 year. Although dysphagia is a typical symptom of myasthenia gravis, swallowing disturbances should not be attributed hastily to this disease, since they may also be a complication of therapy. PMID: 21732154 [PubMed - as supplied by publisher] (Source: Zeitschrift fur Gerontologie und Geriatrie)

Aiming for Zero: Preventing Invasive Candida Infections in Extremely Preterm Infants
Strong evidence shows that prevention of invasive Candida infections (ICI) can be achieved by every neonatal intensive care unit (NICU). Due to the incidence of ICI and high infection-associated mortality and neurodevelopmental impairment, antifungal prophylaxis should be targeted to infants weighing less than 1,000 g or born at or before 27 weeks' gestation. Even in NICUs that have low rates of ICI, antifungal prophylaxis is crucial to improving survival and neurodevelopmental outcomes in this vulnerable population. Strong evidence supports the use of both fluconazole and nystatin for such prophylaxis. Fluconazole is preferred in high-risk preterm infants because intravenous (IV) fluconazole prophylaxis has greater efficacy compared with enteral nystatin prophylaxis, is effective in the m...